Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Maharashtra’s Food and Drug Administration has reportedly issued a public warning against the use of three cosmetic products after laboratory testing detected excessive levels of mercury and lead, rendering them non-compliant with prescribed safety standards. The regulator has advised consumers to avoid using the affected products and has initiated appropriate regulatory action to prevent their sale and distribution. The move underscores the FDA’s continued efforts to safeguard public health by enforcing quality and safety standards for cosmetics.
Source: short-url.cc/1yGXL

2. Food Safety and Standards Authority of India has reportedly issued notices to energy drink brands for their misleading claims of “energy drink on product branding and labelling”. The FSSAI further states that the Food Category System under the Food Safety and Standards Regulations is not intended for product naming or labelling purposes.
Source: short-url.cc/1taa0

3. The Indian Pharmaceutical Association (IPA) has urged the ministry of health and family welfare (MoHFW) to remove AYUSH and Homeopathy provisions from the National Pharmacy Commission Bill, 2026. The association contended that the proposed bill should remain confined to the regulation of modern pharmacy education and practice, stating that the inclusion of traditional systems of medicine could dilute the existing regulatory framework for pharmaceutical sciences.
Source: short-url.cc/1yGXT

4. The Maharashtra Government has introduced the Maharashtra Clinical Establishments (Registration and Regulation) Bill, 2026, to create a comprehensive regulatory framework for clinical establishments. Replacing the Bombay Nursing Homes Registration Act, 1949, the Bill mandates registration, prescribes minimum standards, strengthens patient rights, promotes fee transparency and establishes oversight and enforcement mechanisms.
Source: short-url.cc/1taab

5. The Jharkhand High Court has held that bhang does not fall within the definition of “cannabis (hemp)” under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The Court observed that the statutory definition covers charas, ganja, and specified cannabis preparations, but does not include bhang prepared from cannabis leaves. Accordingly, the Court ruled that the possession or sale of bhang, by itself, does not attract the penal provisions of the NDPS Act, reaffirming the distinction drawn under the statutory framework.
Source: short-url.cc/1taah

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES 19 June

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Maharashtra Food and Drug Administration (FDA) has directed the recall of a Schedule H prescription cough and cold medication manufactured by a leading pharmaceutical company following concerns over its public advertisement. As advertisements of Schedule H drugs are prohibited, the action highlights continued regulatory scrutiny of promotional practices for prescription medicines.
Source: short-url.cc/1sRrA

2. India plans to establish Centres of Excellence to tackle diabetes-related wounds within 2–3 years. Backed by substantial investments, these centres will integrate advanced imaging, AI-enabled monitoring, and multidisciplinary care to reduce complications like foot ulcers and amputations. These centres will also offer multiple qualified health specialists from various areas for wounds.
Source: short-url.cc/1sRrF

3. The Ministry of Health and Family Welfare has notified the amendment to the Surrogacy rules, introducing a framework for the renewal of surrogacy clinic registrations under the Surrogacy (Regulation) Act, 2021. The amendments prescribe the procedure, timelines, inspection requirements, and fees for renewal applications, provide for the utilisation of registration fees by appropriate authorities, and make renewed registrations valid for a further period of three years.
Source: short-url.cc/1ymC2

4. India’s central food authority, Food Safety and Standards Authority of India (FSSAI) has reportedly directed Food Business Operators (FBOs) to ensure that only corrosion-resistant knives and cutting tools are used in food handling, processing, preparation, and packaging activities. FSSAI has emphasized that food-contact materials and equipment must be maintained in a hygienic condition and be made of suitable materials that do not compromise food safety. Food businesses have been advised to review their operational practices and replace non-compliant equipment to ensure adherence to applicable food safety and hygiene requirements. The advisory is aimed at minimizing the risk of physical and chemical contamination arising from rusted or deteriorating equipment coming into contact with food products.
Source: short-url.cc/1ymCb

5. The Ministry of Health and Family Welfare has notified the Assisted Reproductive Technology (Regulation) Amendment Rules, 2026. The amendment inserts Rules 7A and 8A, introducing a formal renewal framework for registration of Assisted Reproductive Technology clinics and banks. It prescribes renewal application procedures, a 60-day pre-expiry filing timeline, renewal fees, and review processes, while clarifying the utilization of registration fees. Renewed registrations will remain valid for five years.
Source: short-url.cc/1sRsz

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. A major food manufactured in the USA has removed all certified artificial colours from its food and beverage portfolio successfully, achieving its goal of fully eliminating them by the middle of this year. This move was announced in June 2025 and was confirmed that more than 90% of its U.S. portfolio was already free from synthetic dyes. These reformulated products have started arriving for consumption in the USA.
Source: short-url.cc/1xs6v

2. Hong Kong’s Department of Health has announced that medical gases will be regulated as pharmaceutical products from June 14, 2026, requiring manufacturers, wholesalers, and retailers to obtain relevant licences. Products containing nitrous oxide and nitric oxide will be classified as prescription medicines. Non-compliance may result in fines, imprisonment, and other regulatory enforcement actions.
Source: short-url.cc/1rZJs

3. The U.S. Food and Drug Administration (FDA) has issued warning letters to multiple entities for alleged violations of current Good Manufacturing Practice (CGMP) requirements and for the unlawful marketing of GLP-1 receptor agonist drugs through telehealth platforms. These warnings address firms that do not meet quality standards and telehealth providers promoting unapproved products for weight loss. The FDA emphasised compliance with manufacturing, quality, and marketing rules, and cautioned that failure to address the identified violations could result in further regulatory action.
Source: short-url.cc/1xs6F

4. India’s Central government has amended the marine export laws for export administration, effective from 9th June 2026. To modernize export administration, the notification mandates online registration workflows and establishes revised fee schedules. The legislative intent is to digitize statutory record-keeping and enforce strict compliance protocols governing ownership transfers, facility modifications, and dealer licensing across vessels, processing plants, and storage premises.
Source: short-url.cc/1rZJV

5. The World Health Organization has urged countries to shift from visual inspection and cytology-based screening to Human Papillomavirus testing for cervical cancer prevention. The updated recommendation highlights superior accuracy in detecting high-risk infections and supports wider adoption of affordable, locally developed Human Papillomavirus tests to accelerate cervical cancer elimination efforts.
Source: short-url.cc/1xs6P

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. USA based company has issued a nationwide recall of its powdered infant formula after the FDA and CDC contacted the company about three infant botulism cases involving babies who had consumed its formula. The affected infants in California, Washington, and Pennsylvania were hospitalized and treated with FDA-approved treatment, with no deaths reported. No formula has tested positive for the bacteria; the recall was made as a precaution.
Source: short-url.cc/1rUTh

2. The Union Health Ministry’s decision to remove cough syrups from the Schedule K exemption may encourage a shift towards Ayurveda, Siddha and Unani remedies, particularly in rural areas where access to doctors and licensed pharmacies is limited. Industry experts expect demand for Ayush cough syrups to rise as access to conventional cough syrups require a prescription for purchase.
Source: short-url.cc/1rUTs

3. IHLD MedTech to reportedly establish a nationwide network of specialized wound-care Centers of Excellence under its Wound Heal Plus initiative. This is important as chronic and non-healing wounds, particularly among diabetic patients, remain a major healthcare challenge. The network will expand access to advanced wound management, rehabilitation, and AI-enabled patient monitoring services.
Source: short-url.cc/1rUTw

4. US FDA has approved updated safety labelling for an OTC weight-loss drug, adding warnings about rare risks of acute kidney injury and kidney stones. The change is important as it alerts consumers and healthcare providers to potential kidney complications, especially among users with kidney disease or a history of kidney stones.
Source: short-url.cc/1xn6Q

5. A recent inspection by the Telangana Medical Council has reignited discussions on the scope of practice and legality of dentists in relation to aesthetic and hair transplantation procedures. The NMC stated that only trained medical professionals should conduct these non-emergency procedures. The NDC allowed oral and maxillofacial surgeons to perform them with proper training. Furthermore, the Telangana Medical Council confirmed that dentists lack the training for such procedures.
 Source: short-url.cc/1xn6U

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Maharashtra FDA Commissioner Tukaram Mundhe issued an Order on June 12, 2026 barring hospitals, doctors, and affiliated pharmacies from compelling patients to buy medicines exclusively from in-house pharmacies. Prescriptions must be handed directly to patients which gives the patients an option to pick pharmacy of their choice. This restriction put by hospitals on the choice of the patient to purchase medicines from their choice of a pharmacy amounts to unfair trade practices under the Consumer Protection Act, 2019. Further, hospitals must now display notices stating patients of their right to purchase medicines from any licensed pharmacy of their choice in English and Marathi.
Source: shortlink.uk/1xhAz

2. The Jharkhand High Court has directed a complete ban on the conduct of the “two-finger test” in all hospitals, medical colleges, and healthcare institutions across the State. Reiterating established legal and medical principles, the Court observed that the practice is unscientific, violates the dignity, privacy, and bodily autonomy of survivors of sexual assault, and has no evidentiary value in determining consent or sexual history. The Court directed the concerned authorities to ensure strict compliance with existing guidelines and legal standards governing the medical examination of sexual assault survivors, while emphasizing the need for survivor-centric and trauma-informed medical care. The ruling reinforces the prohibition on the use of the test and underscores the obligation of healthcare institutions to adhere to prescribed medico-legal protocols.
Source: shortlink.uk/1xgoW

3. The Telangana Drugs Control Administration has reportedly intensified enforcement against illegal medicine distribution by raiding an unauthorized supplier of cardiac stimulant injections and an unlicensed medical shop. Authorities warned against unauthorized sales and supply of prescription medicines.
Source: shortlink.uk/1rOoZ

4. The Supreme Court has reaffirmed that strict compliance with the PCPNDT Act, 1994 is essential to prevent sex-selective practices and female foeticide. The Court held that deficiencies in mandatory records, including Form F, are not mere technical errors but substantive violations. Emphasising the Act’s objective, it observed that accurate documentation is a crucial safeguard for effective monitoring, enforcement, and prevention of unlawful sex determination practices.
Source: shortlink.uk/1xgqd

5.India’s Ministry of Health and Family Welfare has notified an amendment to Drugs Rules, 1945 dated June 9, 2026. The amendment removes the term “Syrups” from Item (7) under Serial No. 13 of Schedule K of the Drugs Rules, 1945. This means that now syrups will be sold under a sales license only. Schedule K specifies certain classes of drugs and categories of persons or institutions that are exempt from specific provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder, subject to prescribed conditions. The amendment came into force on the date of its publication in the Official Gazette.
Source: shortlink.uk/1rOqd

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Through an FIR filed by a health activist, it was found that thirty doctors from nine states were found guilty of accepting luxury foreign trips worth ₹1.9 crore from a pharma company. While 27 names were sent to the NMC, several state medical councils failed to act. The NMC has now sent reminders to State Medical Councils of Assam, Delhi, Karnataka, Kerala, Telangana and WB to expedite action and warning it may intervene if delays persist, to ensure accountability and compliance across medical practice.
Source: shortlink.uk/1wLSY

2. India’s central government is reportedly considering to extend the customs duty exemption on critical petrochemical inputs used by the pharmaceutical industry beyond the current June 30, 2026 deadline. The proposal is being examined in view of continued supply chain disruptions and rising input costs linked to the ongoing geopolitical tensions in West Asia. The duty relief, originally introduced as a temporary measure in April 2026, covers several petrochemical products that serve as key raw materials and intermediates for pharmaceutical manufacturing. Government officials have indicated that an extension may be considered if prevailing conditions continue to impact the availability and cost of essential inputs.
Source: shortlink.uk/1rkQs

3. The Government is reportedly working on a proposal to strengthen the financial viability of Jan Aushadhi Kendras by revising the incentive structure, increasing retailer margins, extending credit periods, and addressing losses arising from expired inventory. Under the proposed measures, product margins for Kendra operators may be gradually increased to as much as 50%, while credit periods for retailers could be extended from 45 days to 75 days to ease working capital requirements. The plan also contemplates mechanisms for absorbing losses on expired medicines and enhancing support across the supply chain. These measures are aimed at improving inventory availability, supporting sustainable operations of Kendras, and facilitating the continued expansion of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) network across the country.
Source: shortlink.uk/1wLTd

4. The Madras High Court has ruled in favour of a pharmaceutical innovator company in a patent infringement dispute concerning the export of an Active Pharmaceutical Ingredient (API). The Court held that the defendant’s export activities were not protected under the Bolar exemption as the defendant failed to produce regulatory documentation demonstrating that the exports were solely for purposes permitted under the provision. The Court further held that a prior consent decree entered into by the defendant operated as issue estoppel, preventing it from subsequently challenging the validity of the patent. Consequently, the Court granted relief restraining the infringing activities and reaffirmed the evidentiary requirements for entities seeking to rely on the Bolar exemption for export-related activities.
Source: shortlink.uk/1wLTi

5. The Delhi High Court has issued notice in a trademark infringement and passing off suit filed by a pharmaceutical company alleging that several medicinal product marks adopted by the defendants are deceptively similar to its registered and applied-for trademarks. The plaintiff contends that the impugned marks are likely to cause confusion and deception among consumers, particularly in the pharmaceutical sector where a higher standard of care is required to avoid medication errors. Considering the plaintiff’s application for interim relief, the Court has sought a response from the defendants and directed them to file their reply within three weeks. The matter will now proceed for consideration of the plaintiff’s request for an ex-parte ad-interim injunction and other reliefs.
Source: shortlink.uk/1wLTw

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Punjab’s Food and Drugs Administration (FDA) has cancelled a pharmaceutical manufacturer’s licence and ordered a nationwide product recall following findings that allegedly linked substandard oxytocin injections to maternal deaths. The action highlights increased scrutiny of GMP compliance and data integrity, signalling stricter enforcement where product quality deficiencies may endanger patient safety.
Source: shortlink.uk/1rjtj

2. Maharashtra’s FDA has uncovered a supply of falsely labelled “sterile” surgical gloves to government hospitals in Mumbai. The gloves were allegedly unsterilised due to company’s sterilization machine was malfunctioning, prompting raids and seizure of stock. The company responsible had attempted to recall the unsterilized surgical gloves before the raid with no success. Authorities are investigating licensing violations and whether proper recall procedures were followed.
Source: shortlink.uk/1rjtr

3. A U.S. federal court has allowed a proposed class-action lawsuit to proceed against a manufacturer of a children’s nutritional drink over allegations that its marketing and packaging misled consumers into believing the product was clinically proven to help children grow taller. The court held that product claims, combined with visual branding and advertising elements, could reasonably be interpreted by consumers as referring to height growth rather than general growth and development. The lawsuit alleges that consumers were misled regarding the product’s benefits, while the company maintains that its claims are scientifically supported and appropriately describe the product’s role in supporting children’s growth and development. The case will now proceed for further judicial consideration.
Source: shortlink.uk/1rjtH

4. India’s Directorate General of Foreign Trade has exempted Special Economic Zone (SEZ) units and developers from the applicability of conditions of Quality Control Orders (QCO) and Bureau of Indian Standards (BIS) rules. This exemption will be applicable on the permissible good imported like raw materials and capital goods which are authorized for SEZ operations. However, if these imported items or their resulting manufactured products are moved into the Domestic Tariff Area (DTA), they will be required to fully comply with all applicable QCO and BIS laws. Additionally, SEZ entities will have to submit a formal undertaking to the Development Commissioner at the time of import.
Source: shortlink.uk/1rjtg

5. The United States Food and Drug Administration is conducting a scientific safety review of mifepristone, the abortion pill, using existing drug safety systems. The review could influence future distribution requirements for the medicine. While the agency maintains that mifepristone is safe and effective when used as directed, abortion rights groups have criticized the review.
Source: shortlink.uk/1rjtT

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Employees’ State Insurance Corporation (ESIC) has launched a centralized online patient feedback system across its hospitals and dispensaries nationwide to strengthen patient-centric healthcare delivery. The digital platform enables beneficiaries to submit feedback on healthcare services received at ESIC facilities, facilitating real-time monitoring of patient experiences and service quality. The initiative will help identify service gaps, support continuous quality improvement, and strengthen the overall healthcare experience for insured persons and their dependents.
Source: shortlink.uk/1rjWU

2. The Himachal Pradesh High Court has quashed criminal proceedings against a liquor manufacturer arising from the transport of liquor consignments where authorities found two liquor cases without a valid permit and bottles bearing batch numbers different from those specified in the permit. The Court observed that the batch-number discrepancies resulted from inadvertent labelling errors by workers, with no evidence of adulteration or revenue loss to the government. Holding that only the transport of the two unpermitted liquor cases constituted an offence, the Court compounded the matter and imposed a monetary penalty, while allowing separate departmental action for licence-condition violations to continue.
Source: shortlink.uk/1wKXJ

3. The Ministry of Health and Family Welfare has notified an amendment to Schedule V of the Drugs Rules, 1945, substituting the unit for folic acid from “mg” (milligram) to “mcg” (microgram). The amendment will come into force six months from the date of its publication in the Official Gazette.
Source: shortlink.uk/1rjX4

4. The Ministry of AYUSH has amended the NCISM appointment rules to reduce the minimum experience required for appointment as Secretary to the Commission from 15 years to 7 years. The amendments also clarify that serving government officials appointed to NCISM or its Autonomous Boards will be treated as being on deputation and provide alternative provident fund coverage where General Provident Fund subscription is unavailable. This strengthens the institutional and human-resource framework of the NCISM, which oversees standards in Indian systems of medicine.
Source: shortlink.uk/1rjWU

5. The National Pharmaceutical Pricing Authority (NPPA) is considering raising prices of key platinum-based cancer drugs like cisplatin and carboplatin after manufacturers flagged steep increases in raw material costs, especially platinum. Authorities are balancing concerns over patient affordability with the risk of supply shortages if prices remain unchanged.
Source: shortlink.uk/1wKXQ

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Central Drugs Standard Control Organization has directed state regulators to strengthen enforcement against the use of Chloramphenicol and Nitrofurans in food-producing animals. The move follows continued detection of these substances in export consignments, leading to international rejections and raising concerns over regulatory compliance and export competitiveness.
Source: shortlink.uk/1wKBT

2. The Food Safety and Standards Authority of India (FSSAI) has notified the Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026, which came into force upon publication in the Official Gazette on 23 May 2026. Through the amendment, FSSAI has omitted clause (8) of sub-regulation 2.3.14 of the Food Safety and Standards (Prohibition and Restrictions on Sales) Regulations, 2011, following consideration of stakeholder comments received on the draft regulations issued in October 2024. The amendment formally revises the existing regulatory framework governing restrictions on the sale of specified food products under the Food Safety and Standards Act, 2006.
Source: shortlink.uk/1wKCp

3. The US FDA has launched a safety study of the abortion pill, also called mifepristone, potentially enabling new restrictions on its distribution and use. The FDA has further said for mifepristone to be safe and effective. Officials say the review is already underway and science based. The study will analyse existing data and could influence abortion access policies. Abortion right was legalised through the Supreme Court’s 2022 ruling which overturned Roe v. Wade.
Source: shortlink.uk/1rjC6

4. A pharmaceutical manufacturer has received a Warning Letter from the United States Food and Drug Administration (USFDA) concerning its formulation manufacturing facility in Baddi, Himachal Pradesh. The regulatory action was issued following a review of records submitted under the US Federal Food, Drug, and Cosmetic Act and is not linked to any on-site inspection of the facility. The observations relate to the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company has stated that the Warning Letter is not expected to impact ongoing operations or product supplies from the facility and has committed to undertaking the necessary corrective actions and responding to the USFDA within the prescribed timelines. The facility was last inspected by the USFDA in August 2025 and subsequently received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification.
Source: shortlink.uk/1wKCB

5. Hospitals across India are reportedly facing shortages of key chemotherapy drugs, including cisplatin and carboplatin, disrupting cancer treatment schedules and forcing patients to search for alternative supplies. The shortage has been linked to supply chain constraints and rising input costs, raising concerns about continuity of care and treatment outcomes.
Source: shortlink.uk/1wKCH

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Directorate General of Foreign Trade(DGFT), issued a Public Notice dated 1 June 2026 and has notified six new Standard Input Output Norms (SIONs) under the Chemical and Allied Product Group for specified pharmaceutical products. The notification enables Regional Authorities to grant Advance Authorisations without case-specific referrals to the Norms Committee, thereby reducing processing timelines, ensuring uniformity in approvals, and promoting ease of doing business for pharmaceutical exporters.
Source: shortlink.uk/1q-yS

2. The Delhi High Court directed CDSCO to review safety concerns over semaglutide injections within two months. A patient petition claims that manual calculation of dosage deviates from global pre-filled pen standards, risking overdose, underdose, and misuse. CDSCO must determine if approval aligns with patient safety and international practices.
Source: shortlink.uk/1q-xi

3. The Indian government is reportedly drafting new organ transplant rules to introduce Donation after Circulatory Death (DCD) and strengthen frameworks for organ swaps and brain-stem death donations. The proposed reforms aim to expand the donor pool, standardise transplant procedures, and improve access to life-saving organ transplants.
Source: shortlink.uk/1q-z5

4. The Maharashtra State Consumer Disputes Redressal Commission has held that obtaining a patient’s signature on a pre-printed consent form without adequately disclosing the nature of the procedure, associated risks, possible complications, and available alternatives does not constitute valid informed consent. The Commission observed that a mere signature on a standardised form cannot satisfy a doctor’s duty of disclosure and ruled that failure to obtain proper informed consent amounts to a deficiency in service. While the Commission found no evidence of medical negligence in the performance of the surgery or post-operative care, it held the medical practitioner liable for not securing valid informed consent and awarded compensation.
Source: shortlink.uk/1q-za

5. The Central Drugs Standard Control Organisation has directed pharmaceutical manufacturers to establish and maintain pharmacovigilance systems in line with revised Schedule M requirements. Companies must maintain dedicated adverse reaction monitoring mechanisms, appoint qualified pharmacovigilance officers and keep detailed records, with compliance subject to regulatory inspections.
Source: shortlink.uk/1q-xq